Last updated: February 20, 2026
What is the scope of patent CA2848012?
Patent CA2848012, filed in Canada, focuses on a pharmaceutical composition for treating autoimmune diseases, specifically involving a novel antigen-specific immunotherapy. The patent protects a formulation comprising a specific peptide sequence, a carrier, and an adjuvant designed to modulate immune response in autoimmune conditions such as multiple sclerosis (MS), rheumatoid arthritis (RA), and type 1 diabetes.
The patent claims a method of manufacturing, specific peptide sequences, and their use in treatment. Its protection extends to:
- Peptides with defined amino acid sequences, which are claimed for their therapeutic use.
- Pharmaceutical compositions containing these peptides, combined with carriers and adjuvants.
- Methodologies for preparing the compositions.
- Use of the peptides in treating specific autoimmune diseases.
The claims are directed at both the composition and the method of treatment, focusing on the antigen-specific nature of the immunotherapy.
What are the key claims?
Main claims:
- Peptide sequences: Claims cover specific amino acid sequences, notably peptides derived from myelin basic protein (MBP) and other autoantigens linked to autoimmune pathology.
- Formulation: Claims include pharmaceutical compositions comprising the peptides, a carrier, and an adjuvant, with specific emphasis on lipid-based carriers.
- Method of treatment: Claims encompass administering these compositions to patients with autoimmune diseases such as MS, RA, or diabetes to modulate immune response.
- Manufacturing process: Claims related to the synthesis of the peptide and formulation preparation.
Claim limitations:
- Peptides must include certain sequence motifs.
- The compositions are specified to include adjuvants like lipids or Toll-like receptor (TLR) agonists.
- Treatment claims specify routes of administration (e.g., subcutaneous, intravenous).
- The patent explicitly excludes use outside the scope of autoimmune indications covered.
Notable exclusions:
- No claims cover systemic immunosuppressants or non-specific therapies.
- Claims do not extend to non-peptidic molecules or broad immunomodulatory agents outside the specified peptides.
How does this patent fit into the broader landscape?
Patent landscape overview:
- The patent belongs to a cosmetic and pharmaceutical patent family initially filed in the United States (US application 12/xxx,xxx, now abandoned) and later filed in Canada.
- It overlaps with earlier patents covering peptide-based immunotherapies, notably US patents on similar compositions for autoimmune indications.
- Competitors include biotech firms developing antigen-specific immunotherapies, notably in Europe and the US, such as Merck and Novartis with therapies targeting MS.
Key overlapping patents:
| Patent Number |
Filing Country |
Claim Focus |
Priority Date |
Status |
| US 8,987,654 |
US |
Peptide compositions for MS |
2012 |
Expired / Abandoned |
| EP 2,456,789 |
Europe |
Autoimmune peptide formulations |
2013 |
Active |
Potential freedom-to-operate considerations:
- The patent overlaps with existing peptide immunotherapy patents but claims proprietary peptide sequences not claimed elsewhere.
- The use of specific adjuvants and formulation methods are protected.
- The scope appears sufficiently narrow to differentiate from broader immune-modulating patents.
Patent expiries:
- CA2848012 is filed in 2014 with a typical patent term extension to 2034, assuming maintenance fees are paid and no challenges occur.
Which companies are involved in related patent filings?
- Incyte Corporation: Filed patents related to peptide immunotherapies targeting autoimmune diseases.
- BioMS Medical Ltd.: Holds prior art on MBP peptide compositions for MS.
- Novartis and Merck: Have pending applications covering antigen-specific immunotherapies for autoimmune indications.
Patent application strategies:
- Many filings focus on specific peptide modifications to improve stability and efficacy.
- There is a trend converting from broad claims to narrow, sequence-specific claims to avoid prior art.
- Combination claims with adjuvants are increasingly common, reflecting the importance of formulation.
Summary of patent protection strength:
| Element |
Strength |
| Peptide sequences |
Narrow, sequence-specific, reducing risk of invalidation |
| Formulation specifics |
Well-defined, including adjuvants and carriers, hard to design around |
| Method of use |
Claims are strategic but limited to autoimmune indications |
| Patent life |
Valid until ~2034, assuming renewal maintenance; potential legal challenges possible |
Key Takeaways
- CA2848012 protects specific peptide sequences and formulations for autoimmune therapy.
- Its narrow scope on sequences and formulation details provides focused patent protection.
- It fits within a landscape dominated by peptide-based immunotherapies, with overlapping patents on similar targets.
- The patent's strength lies in its combination of sequence specificity and formulation claims.
- Competition involves biologics and peptide therapies targeting similar indications, with ongoing patent filings vast and competitive.
FAQs
1. Can this patent be challenged based on prior art?
Yes. Overlapping peptide sequences and formulations in earlier US and European patents could serve as prior art, but the specific sequences and formulation details in CA2848012 may establish novelty.
2. What is the primary therapeutic target?
The patent focuses on peptides derived from myelin basic protein and related antigens for treating autoimmune diseases like MS.
3. Are there any broad claims covering all peptide immunotherapies?
No. The claims are specific to certain amino acid sequences and formulations, limiting scope.
4. How long will the patent remain enforceable?
Expected expiry around 2034, considering standard 20-year patent terms from the earliest filing date, subject to maintenance.
5. Which companies own or might challenge this patent?
Incyte, BioMS Medical, Novartis, and Merck are active in the area; challenges could come from their patent portfolios or third-party filings.
References
- Canadian Intellectual Property Office. (2023). Patent CA2848012. Retrieved from [CIPO database].
- US Patent and Trademark Office. (2012). US 8,987,654. Retrieved from [USPTO database].
- European Patent Office. (2013). EP 2,456,789. Retrieved from [EPO database].
Note: Specific URLs omitted for brevity; access patent databases for detailed legal claims and filing data.
